Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy (FVF4193s)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01255774|
Recruitment Status : Unknown
Verified December 2011 by The New York Eye & Ear Infirmary.
Recruitment status was: Recruiting
First Posted : December 7, 2010
Last Update Posted : December 5, 2011
|Condition or disease||Intervention/treatment||Phase|
|Age Related Macular Degeneration||Drug: ranibizumab||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy Measured Using The Optical Coherence Tomography (OCT) Scanning Laser Ophthalmoscope (SLO) And The Foresee Preferential Hyperacuity Perimeter|
|Study Start Date :||June 2007|
|Estimated Primary Completion Date :||December 2012|
|Estimated Study Completion Date :||December 2012|
Open Label use of Ranibizumab for wet age related macular degeneration
An open-label, study of intravitreally administered ranibizumab
Other Name: Lucentis
- Central retinal thickness [ Time Frame: 12 months ]To measure the mean change in central retinal thickness as measured by OCT/ SLO and Stratus OCT from Baseline to Month 12.
- change in central scotoma lesion size, density and distortion due to neovascularization [ Time Frame: 12 months ]
To measure the mean change in central scotoma lesion size and density as measured on OCT/ SLO microperimeter from Baseline to Month 12.
To measure the mean change in the scotoma size and distortion due to neovascularization as measured on the PHP from Baseline to Month 12.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01255774
|Contact: Katy W Tai, CCRCemail@example.com|
|United States, New York|
|New York Eye and Ear Infirmary||Recruiting|
|New York, New York, United States, 10003|
|Contact: Katy W Tai, CCRC 212-979-4251 firstname.lastname@example.org|
|Principal Investigator:||Richard B Rosen, MD||New York Eye and Ear Infirmary|